Publications

Google Scholar link here. Pubmed link here. Scopus link here

ORCID ID link here.

Some recent journal covers featuring our papers:

List of peer-reviewed publications in international scientific journals:

99.Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design
Hryczanek RP*, Hackett AS, Rowland R, Chung CW, Convery MA, Holmes DS, Hutchinson JP, Kitchen S, Korczynska J, Law RP, Lea JD, Liddle J, Lonsdale R, Neu M, Nickels L, Phillipou A, Rowedder JE, Schneck JL, Scott-Stevens P, Sheehan H, Tayler CL, Temponeras I, Tinworth CP, Walker AL, Wojno-Picon J, Young RJ, Lindsay DM and Stratikos E.
ACS Medicinal Chemistry Letters, 2024, accepted for publication.

98. Polymorphic positions 349 and 725 of the autoimmunity- protective allotype 10 of ER aminopeptidase 1 are key in determining its unique enzymatic properties.
Georgaki G, Mpakali A, Trakada M, Papakyriakou A and Stratikos E*.
Frontiers in Immunology, 2024, 18 October 2024, Volume 15, https://doi.org/10.3389/fimmu.2024.1415964.

97. Stabilization of the open conformation οf Insulin-Regulated Aminopeptidase by a novel substrate-selective small molecule inhibitor
Mpakali A, Georgaki G, Buson A, Findlay AD, Foot JS, Mauvais FX, van Endert P, Giastas P, Hamprecht DW* and Stratikos E*
Protein Science, 2024, Sep;33(9):e5151. doi: 10.1002/pro.5151.

96. Library screening identifies commercial drugs as potential structure correctors of abnormal apolipoprotein A-I
Gkolfinopoulou C, Bourtsala A, Georgiadou D, Dedemadi AG, Stratikos E and Chroni E
J Lip Res 2024, May; 65(5): 100543.

95. Mechanisms of allosteric inhibition of Insulin- Regulated Aminopeptidase
Mpakali A, Barla I, Lu L, Ramesh KM, Thomaidis N, Stern LJ, Giastas P, and Stratikos E*
J Mol Biol 2024, 2024 Mar 15;436(6):168449

94. Distinct modulation of cellular immunopeptidome by the allosteric regulatory site of ER aminopeptidase 1
Temponeras I, Samiotaki M, Koumantou D, Nikopaschou M, Kuiper JJ, Panayotou G, Stratikos E*
Eur J Immunol 2023, Aug;53(8):e2350449

93. EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders.
Kuiper JJW, Prinz JC, Stratikos E, ..., Turkstra F*
Ann Rheum Dis 2023, dx.doi.org/10.1136/ard-2022-222852

92. Phosphinic Peptides as Tool Compounds for the Study of Pharmacologically Relevant Zn-Metalloproteases.
Georgiadis D*, Skoulikas N, Papakyriakou A, and Stratikos E
ACS Pharmacol. Transl. Sci. 2022, https://doi.org/10.1021/acsptsci.2c00183

91. Discovery of the First Selective Nanomolar Inhibitors of Endoplasmic Reticulum Aminopeptidase 2 by Kinetic Target-Guided Synthesis
Camberlein V, Charlotte FT, Sierocki P, Li L, Gealageas R, Bosc D, Guillaume V, Warenghem S, Leroux F, Rosell M, Cheng K, Medve L, Prigent M, Decanter M, Dumont J, Mpakali A, Giastas P, Herledan A, Couturier C, Haupenthal J, Lesire L, Hirsch AK, Deprez B, Stratikos E, Bouvier M, Deprez-Poulain R*
Angew Chem Int Ed Engl. 2022 Jul 29. doi: 10.1002/anie.202203560

90. Discovery of Selective Nanomolar Inhibitors for Insulin- Regulated Aminopeptidase Based on α-Hydroxy-β-Amino Acid Derivatives of Bestatin
Vourloumis D, Mavridis I, Athanasoulis A, Temponeras I, Koumantou S, Giastas P, Mpakali A, Magrioti V, Leib J, van Endert P, Stratikos E* and Papakyriakou A*
J Med Chem, 2022, Jul 14. doi: 10.1021/acs.jmedchem.2c00904

89. Can ERAP1 and ERAP2 Form Functional Heterodimers? A Structural Dynamics Investigation
Papakyriakou A*, Mpakali A and Stratikos E*
Front Immunol, 2022 Apr 20;13:863529. doi: 10.3389/fimmu.2022.863529

88. ERAP2 Inhibition Induces Cell-Surface Presentation by MOLT-4 Leukemia Cancer Cells of Many Novel and Potentially Antigenic Peptides
Temponeras I, Stamatakis G, Samiotaki M, Georgiadis D, Pratsinis H, Panayotou G and Stratikos E*
Int J Mol Sci, 2022 in press

87. Inhibitor-Dependent Usage of the S1′ Specificity Pocket of ER Aminopeptidase 2
Mpakali A*, Georgiadis D, Stratikos E, and Giastas P*
ACS Med. Chem. Lett. 2022 in press

86. Tunable Hydrogels with Improved Viscoelastic Properties from Hybrid Polypeptides
Skoulas D, Mangiapia G, Parisi D, Kasimatis M, Glynos E, Stratikos E, Vlassopoulos D, Frielinghaus H, and Iatrou H
Macromolecules, 2021, November 16, 2021, https://doi.org/10.1021/acs.macromol.1c01596.

85. Allotypic variation in antigen processing controls antigenic peptide generation from SARS-CoV-2 S1 Spike Glycoprotein
Stamatakis G, Samiotaki M, Temponeras I, Panayotou G, Stratikos E.*
JBC, 2021, Oct 21:101329. doi: 10.1016/j.jbc.2021.101329.

84. Conformational dynamics linked to domain closure and substrate binding explain the ERAP1 allosteric regulation mechanism
Maben Z, Arya R, Georgiadis D, Stratikos E, Stern LJ.
Nature Communications, 2021,Sep 6;12(1):5302. doi: 10.1038/s41467-021-25564-w.

83. The ERAP1 active site cannot productively access the N-terminus of antigenic peptide precursors stably bound onto MHC class I
Mavridis G, Mpakali A, Zoidakis J, Makridakis M, Vlahou A, Kaloumenou E, Ziotopoulou A, Georgiadis D, Papakyriakou A and Stratikos E*
Scientific Reports, 2021 Aug 13;11(1):16475. doi: 10.1038/s41598-021-95786-x

82. Discovery of Selective Inhibitor Leads by Targeting an Allosteric Site in Insulin-Regulated Aminopeptidase
Temponeras I, Chiniadis L, Papakyriakou A* and Stratikos E*
Pharmaceuticals 2021, 14(6), 584; https://doi.org/10.3390/ph14060584

81.Editorial: Physiological, Pathological Roles and Pharmacology of Insulin Regulated Aminopeptidase
Siew Yeen Chai, Hugo Gutiérrez De Teran and Efstratios Stratikos*
Front. Mol. Biosci. 2021 | doi: 10.3389/fmolb.2021.685101

80. Common allotypes of ER aminopeptidase 1 have substrate-dependent and highly variable enzymatic properties
Jonathan P. Hutchinson, Ioannis Temponeras, Jonas Kuiper, Adrian Cortes, Justyna Korczynska, Semra Kitchen and Efstratios Stratikos*
J Biol Chem. 2021 Jan-Jun;296:100443. doi: 10.1016/j.jbc.2021.100443. Epub 2021 Feb 20.

79. A Carbodiimide-Mediated P-C Bond-Forming Reaction: Mild Amidoalkylation of P-Nucleophiles by Boc-Aminals
Kokkala, Paraskevi; Rajeshkumar, Thayalan ; Mpakali, Anastasia; Stratikos, Efstratios; Vogiatzis, Konstantinos; Georgiadis, Dimitris
Org Lett. 2021 Mar 5;23(5):1726-1730. doi: 10.1021/acs.orglett.1c00155. Epub 2021 Feb 22.

78. ERAP2 Increases the Abundance of a Peptide Submotif Highly Selective for the Birdshot Uveitis-Associated HLA-A29
W.J. Venema, S. Hiddingh, J.H. de Boer, F.H.J. Claas, A Mulder, A.I. Den Hollander, E. Stratikos, S. Sarkizova, L.T. van der Veken, G.M.C. Janssen, P.A. van Veelen, J.J.W. Kuiper
Frontiers in Immunology 2021, accepted for publication

77. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.
Mpakali, A.; Stratikos, E*.
Cancers 2021, 13, 134.

76. Generation of SARS-CoV-2 S1 spike glycoprotein putative antigenic epitopes in vitro by intracellular aminopeptidases

Stamatakis G, Samiotaki M, Mpakali A, Panayotou G, Stratikos E*.

J Proteome Res. 2020 Sep 15. doi: 10.1021/acs.jproteome.0c00457. (read paper)

75. Structure–function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk

Gkolfinopoulou C, Soukou F, Dafnis I, Kellici TF, Sanoudou D, Mavromoustakos T, Stratikos E & Chroni A*

Cell Mol Life Sci 2020, doi.org/10.1007/s00018-020-03583-y

74. Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor.

Mpakali A, Saridakis E, Giastas P, Maben Z, Stern LJ, Larhed M, Hallberg M, and Stratikos E*

ACS Med. Chem. Lett. 2020, doi.org/10.1021/acsmedchemlett.0c00172 (DOWNLOAD)

73. A systematic re-examination of processing of MHCI-bound antigenic peptide precursors by ER aminopeptidase 1.

Mavridis G, Arya R, Domnick A, Zoidakis J, Makridakis M, Vlahou A, Mpakali A, Lelis A, Georgiadis D, Tampé R, Papakyriakou A, Stern LJ, Stratikos E*. (Editor's Choice, Cover)

J Biol Chem. 2020 Mar 17. pii: jbc.RA120.012976. doi: 10.1074/jbc.RA120.012976.

72. The Differential Expression of ERAP1/ERAP2 and Immune Cell Activation in Pre-eclampsia

Seamon K, Kurlak LO, Warthan M, Stratikos E, Strauss JF 3rd, Mistry HD, Lee ED*.

Front Immunol. 2020. Mar 10;11:396. doi: 10.3389/fimmu.2020.00396. eCollection 2020.

71. Targeting the regulatory site of ER aminopeptidase 1 leads to the discovery of a natural product modulator of antigen presentation. (read here)

Liddle J, Hutchinson JP, Kitchen S, Rowland P, Neu M, Cecconie T, Holmes DS, Jones EJ, Korczynska J, Koumantou D, Lea J, Nickels LA, Pemberton M, Phillipou A, Schneck JL, Sheehan H, Tinworth CP, Uings I, Wojno-Picon J, Young RJ, Stratikos E*.

J Med Chem. 2020 Feb 28. doi: 10.1021/acs.jmedchem.9b02123.

70. Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1.

Maben Z, Arya R, Rane D, An WF, Metkar S, Hickey M, Bender S, Ali A, Nguyen TT, Evnouchidou I, Schilling RJ, Stratikos E, Golden JE, Stern LJ.

J Med Chem. 2019 Dec 16. doi: 10.1021/acs.jmedchem.9b00293.

69. Mechanism for antigenic peptide selection by ER aminopeptidase 1.

Giastas P#, Mpakali A#, Papakyriakou A, Lelis A, Kokkala P, Neu M, Rowland P, Liddle J, Georgiadis D and Stratikos E*.

PNAS 2019, December 16, 2019 https://doi.org/10.1073/pnas.1912070116.

68. Macromolecular Architecture and Encapsulation of the Anticancer Drug Everolimus Control the Self-Assembly of Amphiphilic Polypeptide-Containing Hybrids.

Karatzas A, Haataja JS, Skoulas D, Bilalis P, Varlas S, Apostolidi P, Sofianopoulou S, Stratikos E, Houbenov N, Ikkala O, Iatrou H.

Biomacromolecules. 2019 Nov 18.

67. Exploration of zinc-binding groups for the design of inhibitors for the oxytocinase subfamily of M1 aminopeptidases.

Tsoukalidou S, Kakou M, Mavridis I, Koumantou D, Calderone V, Fragai M, Stratikos E, Papakyriakou A, Vourloumis D.

Bioorg Med Chem. 2019 Nov 1:115177.

66. Editing the immunopeptidome of melanoma cells using a potent inhibitor of Endoplasmic Reticulum aminopeptidase. (read paper here)

Koumantou D, Barnea E, Martin-Esteban A, Maben A, Papakyriakou A, Mpakali A, Kokkala P, Pratsinis H, Georgiadis D, Stern LJ, Admon A and Stratikos E*

Cancer Immunol Immunother 2019, Jun 20. doi: 10.1007/s00262-019-02358-0.

65. Endoplasmic reticulum aminopeptidases as a double-faced tool to increase or decrease efficiency of antigen presentation in health and disease.

Kuśnierczyk P, Stratikos E.

Hum Immunol. 2019 Mar 27. pii: S0198-8859(19)30296-4. doi: 10.1016/j.humimm.2019.03.011.

64. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.

Delimitsou A, Fostira F, Kalfakakou D, Apostolou P, Konstantopoulou I, Kroupis C, Papavassiliou AG, Kleibl Z, Stratikos E, Voutsinas GE, Yannoukakos D.

Hum Mutat. 2019 Mar 9. doi: 10.1002/humu.23728.

63. Endoplasmic reticulum aminopeptidase 1 polymorphism Ile276Met is associated with atopic dermatitis and affects the generation of an HLA-C associated antigenic epitope in vitro.

Niepiekło-Miniewskaa W,*, Mpakali A,*, Stratikos E, Matusiak L, Narbutt J, Lesiak A, Kuna P, Wilczyńska K, Nowak I, Wiśniewski A, Zwolińska K, Ponińska J, Płoski R, Szepietowskic JC, Kuśnierczyka P

J Eur Acad Dermatol Venereol 2019, Jan 25. doi: 10.1111/jdv.15449

62. High-Resolution Crystal Structure of Endoplasmic Reticulum Aminopeptidase 1 with Bound Phosphinic Transition-State Analogue Inhibitor. (COVER)

Giastas P, Neu M, Rowland P, Stratikos E*.

ACS Med Chem Lett. 2019 Feb 13;10(5):708-713. doi: 10.1021/acsmedchemlett.9b00002

61. Intracellular Antigen Processing by ERAP2: Molecular Mechanism and Roles in Health and Disease.

de Castro JAL, Stratikos E*.

Hum Immunol. 2018 Nov 7. pii: S0198-8859(18)30785-7. doi: 10.1016/j.humimm.2018.11.001

60. Aminobenzosuberone Scaffold as a Modular Chemical Tool for the Inhibition of Therapeutically Relevant M1 Aminopeptidases.

Salomon E, Schmitt M, Marapaka AK, Stamogiannos A, Revelant G, Schmitt C, Alavi a, Florent I, Addlagatta A, Stratikos E, Tarnus C and Albrecht S*

Molecules 2018, 23(10), 2607; https://doi.org/10.3390/molecules23102607

59. Thermodynamic destabilization and aggregation propensity as the underlying mechanism behind the genetic association of apoE3 mutants and Lipoprotein Glomerulopathy.

Katsarou M, Stratikos E*, Chroni A*.

J Lipid Res. 2018 Oct 11. pii: jlr.M088732. doi: 10.1194/jlr.M088732

58. Self-Healing pH- and Enzyme Stimuli-Responsive Hydrogels for Targeted Delivery of Gemcitabine To Treat Pancreatic Cancer.

Bilalis P, Skoulas D, Karatzas A, Marakis J, Stamogiannos A, Tsimblouli C, Sereti E, Stratikos E, Dimas K, Vlassopoulos D, Iatrou H*.

Biomacromolecules. 2018 Aug 27. doi: 10.1021/acs.biomac.8b00959.

57. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.

Konstanta I, Fostira F, Apostolou P, Stratikos E, Kalfakakou D, Pampanos A, Kollia P, Papadimitriou C, Konstantopoulou I, Yannoukakos D.

J Hum Genet. 2018 Aug 15. doi: 10.1038/s10038-018-0498-8.

56. Molecular pathways for antigenic peptide generation by ER aminopeptidase 1

Mpakali A, Maben Z, Stern LJ, Stratikos E*.

Mol Immunol 2018, in press, doi.org/10.1016/j.molimm.2018.03.026

55. Inhibitors of ER aminopeptidase 1 and 2: from design to clinical application.

Georgiadis D, Mpakali A, Koumantou D, Stratikos E*

Curr Med Chem. 2018 Feb 13. doi: 10.2174/0929867325666180214111849. [Epub ahead of print]

54. The role of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) in modulating immune detection of choriocarcinoma.

Warthan MD, Washington SL, Franzese SE, Ramus RM, Kim KR, York TP, Stratikos E, Strauss SF III, and Lee ED

Biology of Reproduction 2018, ioy001, https://doi.org/10.1093/biolre/ioy001

53. The Role of Conformational Dynamics in Antigen Trimming by Intracellular Aminopeptidases.

Papakyriakou A* and Stratikos E*.

Front Immunol 2017, doi: 10.3389/fimmu.2017.00946

52. Ligand-induced conformational change of Insulin-regulated aminopeptidase: insights on catalytic mechanism and active site plasticity.

Mpakali A, Saridakis E, Harlos K, Zhao Y, Kokkala P, Georgiadis D, Giastas P, Papakyriakou A, Stratikos E*

J Med Chem. 2017 Mar 22. doi: 10.1021/acs.jmedchem.6b01890

51. The Pivotal Role of Protein Phosphorylation in the Control of Yeast Central Metabolism.

Vlastaridis P, Papakyriakou A, Chaliotis A, Stratikos E, Oliver SG, Amoutzias GD.

G3 (Bethesda). 2017 Mar 1. pii: g3.116.037218. doi: 10.1534/g3.116.037218.

50. Crystal Structures of ERAP2 Complexed with Inhibitors Reveal Pharmacophore Requirements for Optimizing Inhibitor Potency

Mpakali A, Giastas P, Deprez-Poulain R, Papakyriakou A, Koumantou D, Gealageas R, Tsoukalidou S, Vourloumis D, Mavridis IM, Stratikos E and Emmanuel Saridakis

ACS Med. Chem. Lett. 2017 doi: 10.1021/acsmedchemlett.6b00505

49. Critical role of inter-domain interactions on the conformational change and catalytic mechanism of Endoplasmic Reticulum Aminopeptidase 1.

Stamogiannos A, Maben Z, Papakyriakou A, Mpakali A, Kokkala P, Georgiadis D, Stern LJ, Stratikos E*.

Biochemistry. 2017 Feb 20. doi: 10.1021/acs.biochem.6b01170.

48. Optimization and Structure-Activity Relationships of Phosphinic Pseudotripeptide Inhibitors of Aminopeptidases that Generate Antigenic Peptides.

Kokkala P, Mpakali A, Mauvais FX, Papakyriakou A, Daskalaki I, Petropoulou I, Kavvalou S, Papathanasopoulou M, Agrotis S, Fonsou TM, van Endert P, Stratikos E*, Georgiadis D*.

J Med Chem 2016, Oct 13;59(19):9107-9123

47. The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific.

Dafnis I, Argyri L, Sagnou M, Tzinia A, Tsilibary EC, Stratikos E, Chroni A.

Sci Rep. 2016 Aug 1;6:30654. doi: 10.1038/srep30654.

46. Screening Identifies Thimerosal as a Selective Inhibitor of Endoplasmic Reticulum Aminopeptidase 1.

Stamogiannos A, Papakyriakou A, Mauvais FX, van Endert P, Stratikos E*.

ACS Med Chem Lett. 2016 May 31;7(7):681-5

45. Structural basis for antigenic peptide recognition and processing by ER aminopeptidase 2.

Mpakali A, Giastas P, Mathioudakis N, Mavridis IM, Saridakis E*, Stratikos E*.

J Biol Chem. 2015 Sep 17. pii: jbc.M115.685909.

44. Crystal structure of Insulin Regulated Aminopeptidase with bound substrate analogue provides insight on antigenic epitope precursor recognition and processing.

Mpakali A, Saridakis E, Harlos K, Zhao Y, Papakyriakou A, Kokkala P, Georgiadis D, Stratikos E*.

J Immunol. 2015 Aug 10. pii: 1501103.

43. Effects of polymorphic variation on the mechanism of Endoplasmic Reticulum Aminopeptidase 1.

Stamogiannos A, Koumantou D, Papakyriakou A*, Stratikos E*.

Mol Immunol. 2015 Jul 26. pii: S0161-5890(15)30019-5.

42. Impaired antiatherogenic functions of high-density lipoprotein in patients with Ankylosing Spondylitis.

Gkolfinopoulou C, Stratikos E, Theofilatos D, Kardassis D, Voulgari PV, Drosos AA and Chroni A.

J Rheumatol 2015 Aug 1. pii: jrheum.141532.

41. 3,4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune regulating properties.

Papakyriakou A, Zervoudi E, Tsoukalidou S, Mauvais FX, Sfyroera G, Mastellos DC, van Endert P, Theodorakis E, Vourloumis D* and Stratikos E*.

J Med Chem 2015 Feb 12;58(3):1524-43

40. Autoimmune Disease-Associated Variants of Extracellular Endoplasmic Reticulum Aminopeptidase 1 Induce Altered Innate Immune Responses by Human Immune Cells.

Aldhamen YA, Pepelyayeva Y, Rastall DP, Seregin SS, Zervoudi E, Koumantou D, Aylsworth CF, Quiroga D, Godbehere S, Georgiadis D, Stratikos E, Amalfitano A.

J Innate Immun. 2015 Jan 14.

39. A role for naturally occurring alleles of Endoplasmic Reticulum Aminopeptidases in tumor immunity and cancer predisposition

Stratikos, E*, Stamogiannos, A., Zervoudi, E., Fruci, D.

Front. Oncol. 2014 4:363. doi: 10.3389/fonc.2014.00363

38. Regulating adaptive immune responses using small molecule modulators of aminopeptidases that process antigenic peptides.

Stratikos E*.

Curr Opin Chem Biol. 2014 Aug 28;23C:1-7

37. Molecular basis for increased risk for late-onset Alzheimer's disease due to the naturally occurring Leu28Pro mutation in apolipoprotein E4.

Argyri L, Dafnis I, Theodossiou TA, Gantz D, Stratikos E*, Chroni A*.

J Biol Chem. 2014 Mar 18.

36. Modulating antigen processing for cancer immunotherapy.

Stratikos E*.

OncoImmunology, 2014 Volume 3, Issue 1, e27568.

35. A rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses.

Zervoudi E, Saridakis E, Birtley JR, Seregin S., Reeves E, Kokkala P, Aldhamen YA, Amalfitano A, Mavridis IM, James E, Georgiadis D* and Stratikos E*.

Proc Natl Acad Sci USA, 2013 Dec 3;110(49):19890-5.

34. Significance of the hydrophobic residues 225 to 230 of apoA-I for the biogenesis of HDL.

Fotakis P, Tiniakou I, Kateifides AK, Gkolfinopoulou C, Chroni A, Stratikos E, Zannis VI, Kardassis D.

J Lipid Res. 2013 Oct 12. [Epub ahead of print]

33. A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Stratikos E, Chroni A.

Clin Exp Nephrol. 2013 Oct 23 [Epub ahead of print]

32. Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens.

Seregin SS, Rastall DP, Evnouchidou I, Aylsworth CF, Quiroga D, Kamal RP, Godbehere-Roosa S, Blum CF, York IA, Stratikos E, Amalfitano A.

Autoimmunity. 2013 Sep 13. [Epub ahead of print]

31. Role of the hydrophobic and charged residues in the 218 to 226 region of apoA-I in the biogenesis of HDL.

Fotakis P, Kateifides A, Gkolfinopoulou C, Georgiadou D, Beck M, Grundler K, Chroni A, Stratikos E, Kardassis D, Zannis VI.

J Lipid Res. 2013 Aug 29. [Epub ahead of print]

30. Novel selective inhibitors of aminopeptidases that generate antigenic peptides.

Papakyriakou A, Zervoudi E, Theodorakis EA, Saveanu L, Stratikos E, Vourloumis D.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4832-6.

29. A novel ERAP2 haplotype structure in a Chilean population: implications for ERAP2 protein expression and preeclampsia risk.

Derek L. Vanhille, Lori D. Hill, DaShaunda D. Hilliard, Eun D. Lee, Maria E. Teves, Sindhu Srinivas, Juan P. Kusanovic, Ricardo Gomez, Efstratios Stratikos, Michal A. Elovitz, Roberto Romero, Jerome F. Strauss III*

Mol Gen & Gen Med. 2013, v.1, pp 98-107.

28. Antigenic peptide trimming by ER aminopeptidases-Insights from structural studies.

Stratikos E*, Stern LJ*.

Mol Immunol. 2013 Oct;55(3-4):212-9.

27. Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles.

Georgiadou D, Chroni A, Drosatos K, Kypreos KE, Zannis VI, Stratikos E*

Atherosclerosis 2013 Feb;226(2):385-91.

26. Thermodynamic and structural destabilization of apolipoprotein E3 by hereditary mutations associated with the development of Lipoprotein Glomerulopathy.

Georgiadou D, Stamatakis K, Efthimiadou E, Kordas G, Gantz D, Chroni A*, Stratikos E*.

J Lipid Res. 2013 Jan;54(1):164-76.

25. Apolipoprotein A-IV promotes the biogenesis of apoA-IV containing HDL particles with theparticipation of ABCA1 and LCAT.

Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L,Stratikos E, Kardassis D, Zannis VI.

J Lipid Res. 2013 Jan;54(1):107-15.

24. A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing.

Evnouchidou I, Birtley J, Seregin S, Papakyriakou A, Zervoudi E, Samiotaki M, Panayotou G, Giastas P, Petrakis O, Georgiadis D, Amalfitano A, Saridakis E, Mavridis IM and Stratikos E*

J Immunol. 2012, Sep 1;189(5):2383-92.

23. Crystal Structure of Human ER Aminopeptidase 2 Reveals Atomic Basis for Distinct Roles in Antigen Processing.

Birtley JR, Saridakis E, Stratikos E*, Mavridis IM*.

Biochemistry 2012 Jan 10;51(1):286-95.

22. Biophysical analysis of apolipoprotein E3 variants linked with development of Type III Hyperlipoproteinemia

Georgiadou D, Chroni A, Vezeridis A, Zannis VI and Stratikos E*

PLoS ONE, 2011;6(11):e27037

21. Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1.

Kim S, Lee S, Shin J, Kim Y, Evnouchidou I, Kim D, Kim YK, Kim YE, Ahn JH, Riddell SR, Stratikos E, Kim VN, Ahn K.

Nat Immunol. 2011 Sep 4. doi: 10.1038/ni.2097.

20. A simple approach for human recombinant apolipoprotein E4 expression and purification.

Argyri L, Skamnaki V, Stratikos E, Chroni A.

Protein Expr Purif. 2011 Jun 25.

19. Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides.

Zervoudi E, Papakyriakou A, Georgiadou D, Evnouchidou I, Gajda A, Poreba M, Salvesen GS, Drag M, Hattori A, Swevers L, Vourloumis D, Stratikos E*

Biochem J. 2011 Feb 11.

18. Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1.

Nguyen TT, Chang SC, Evnouchidou I, York IA, Zikos C, Rock KL, Goldberg AL, Stratikos E, Stern LJ.

Nat Struct Mol Biol. 2011 Apr 10.

17. Coding single nucleotide polymorphisms of endoplasmic reticulum aminopeptidase 1 can affect antigenic Peptide generation in vitro by influencing basic enzymatic properties of the enzyme.

Evnouchidou I, Kamal RP, Seregin SS, Goto Y, Tsujimoto M, Hattori A, Voulgari PV, Drosos AA, Amalfitano A, York IA, Stratikos E*

J Immunol. 2011 Feb 15;186(4):1909-13.

16. Placental leucine aminopeptidase efficiently generates mature antigenic peptides in vitro but in patterns distinct from endoplasmic reticulum aminopeptidase 1.

Georgiadou D, Hearn A, Evnouchidou I, Chroni A, Leondiadis L, York IA, Rock KL, Stratikos E*

J Immunol. 2010 Aug 1;185(3):1584-92.

15. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42.

Dafnis I, Stratikos E, Tzinia A, Tsilibary EC, Zannis VI, Chroni A.

J Neurochem. 2010 Nov;115(4):873-84.

14. A continuous fluorigenic assay for the measurement of the activity of endoplasmic reticulum aminopeptidase 1: competition kinetics as a tool for enzyme specificity investigation.

Evnouchidou I, Berardi MJ, Stratikos E*

Anal Biochem. 2009 Dec 1;395(1):33-40.

13. A new role for Zn(II) aminopeptidases: antigenic peptide generation and destruction.

Evnouchidou I, Papakyriakou A, Stratikos E*

Curr Pharm Des. 2009;15(31):3656-70.

12. Cellular mechanisms that edit the immunopeptidome and modulate the immune response.

Georgiadou D and Stratikos E*

Current Proteomics, 2009, v.6 (1).

11. The internal sequence of the peptide-substrate determines its N-terminus trimming by ERAP1.

Evnouchidou I, Momburg F, Papakyriakou A, Chroni A, Leondiadis L, Chang SC, Goldberg AL, Stratikos E*

PLoS One. 2008;3(11):e3658.

10. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties.

Chroni A, Pyrpassopoulos S, Thanassoulas A, Nounesis G, Zannis VI, Stratikos E*

Biochemistry. 2008 Sep 2;47(35):9071-80.

9. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain.

Stratikos E*, Wiley DC, Stern LJ.

J Immunol. 2004 Jan 15;172(2):1109-17.

8. Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DR1 by formation of tethered complexes that present enhanced HLA-DM catalysis.

Stratikos E*, Mosyak L, Zaller DM, Wiley DC.

J Exp Med. 2002 Jul 15;196(2):173-83.

7. Structural similarity of the covalent complexes formed between the serpin plasminogen activator inhibitor-1 and the arginine-specific proteinases trypsin, LMW u-PA, HMW u-PA, and t-PA: use of site-specific fluorescent probes of local environment.

Backovic M, Stratikos E, Lawrence DA, Gettins PG.

Protein Sci. 2002 May;11(5):1182-91.

6. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A.

Stratikos E, Gettins PG.

PNAS USA. 1999 Apr 27;96(9):4808-13.

5. Change in environment of the P1 side chain upon progression from the Michaelis complex to the covalent serpin-proteinase complex.

Futamura A, Stratikos E, Olson ST, Gettins PG.

Biochemistry. 1998 Sep 22;37(38):13110-9.

4. Mapping the serpin-proteinase complex using single cysteine variants of alpha1-proteinase inhibitor Pittsburgh.

Stratikos E, Gettins PG.

J Biol Chem. 1998 Jun 19;273(25):15582-9.

3. Major proteinase movement upon stable serpin-proteinase complex formation.

Stratikos E, Gettins PG.

PNAS USA. 1997 Jan 21;94(2):453-8.

2. Recombinant human pigment epithelium-derived factor (PEDF): characterization of PEDF overexpressed and secreted by eukaryotic cells.

Stratikos E, Alberdi E, Gettins PG, Becerra SP.

Protein Sci. 1996 Dec;5(12):2575-82.

1. Simultaneous determination of naproxen and its desmethyl metabolite in human serum by second-derivative synchronous fluorescence spectrometry.

Konstantianos DG, Ioannou PC, Stratikos E.

Analytica Chimica Acta, 290 (1994) 34-39.

* Corresponding author

Efstratios Stratikos

Associate Professor, Chemistry

Publications

Contact Details